Altimmune to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Altimmune (Nasdaq: ALT) announced participation in two upcoming healthcare investor conferences in June 2026, featuring management fireside chats.

Events include the Jefferies Global Healthcare Conference in New York on June 4 and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 10, with webcasts on Altimmune's website.

News Market Reaction – ALT

+1.71%

+1.71% Session close to close

In the May 27 session, ALT gained 1.71%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

• 2026 Jefferies Global Healthcare Conference
  Thursday, June 4, 2026
  Fireside chat at 12:50 p.m. ET
  New York, NY
  

• Goldman Sachs 47^th Annual Global Healthcare Conference
  Wednesday, June 10, 2026
  Fireside chat at 8:00 a.m. ET
  Miami Beach, FL
  

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com

Media Contact:
Real Chemistry
altimmune@realchemistry.com

FAQ

When will Altimmune (ALT) present at the 2026 Jefferies Global Healthcare Conference?

Altimmune will hold a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET. According to Altimmune, the event will take place in New York, NY, with a webcast available online.

What are the details of Altimmune (ALT) at the Goldman Sachs 47th Annual Global Healthcare Conference 2026?

Altimmune is scheduled for a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 8:00 a.m. ET. According to Altimmune, this event will be held in Miami Beach, FL, and webcast for investors.

How can investors access the Altimmune (ALT) investor conference webcasts in June 2026?

Investors can access Altimmune’s June 2026 conference fireside chat webcasts through the Events section of the company’s website. According to Altimmune, both the Jefferies and Goldman Sachs presentations will be available for online viewing for interested stakeholders.

Why is Altimmune (ALT) participating in June 2026 healthcare investor conferences?

Altimmune is joining major June 2026 healthcare investor conferences to engage investors and discuss its late-stage clinical programs. According to Altimmune, management will present in fireside chats, offering updates on its development of pemvidutide for serious liver diseases.

What is Altimmune (ALT) developing that may interest investors at these 2026 conferences?

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases. According to Altimmune, this development program underpins its participation in the June 2026 Jefferies and Goldman Sachs healthcare investor conferences and related webcasts.